Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure

R J M de Vries, P H J M Dunselman, U G Chin Kon Sung, D J van Veldhuisen, H M A Corbeij, W H van Gilst, K I Lie

Abstract

Objective—To evaluate the efficacy and safety of the second generation dihydropyridine calcium channel blocker lacidipine in patients with heart failure.

Design—Placebo controlled, parallel group, double blind study over 8 weeks.

Setting—General community hospital in Breda, The Netherlands.

Patients—A random sample was studied of 25 outpatients with symptoms of mild to moderate heart failure, despite treatment with diuretics, digoxin, and angiotensin converting enzyme inhibitors. Their mean age was 65 years, with mean left ventricular ejection fraction of 0.24 and a peak oxygen consumption of 14.4 mU/min/kg. Two patients dropped out on lacidipine, one patient on placebo.

Intervention—Treatment with lacidipine 4 mg once daily or placebo for eight weeks.

Main outcome measure—Cardiopulmonary exercise testing, invasive haemodynamics, and plasma neurohormones.

Results—Treatment with lacidipine 4 mg once daily, as compared to placebo treatment, significantly improved peak oxygen consumption (P < 0.02), cardiac index (P < 0.01), and stroke volume (P < 0.03) paralleled by a decrease in systemic vascular resistance (P < 0.03) and arteriovenous oxygen content difference (P < 0.01). Plasma noradrenaline, plasma renin activity, and aldosterone values did not differ between lacidipine and placebo.

Conclusions—This second generation dihydropyridine may be of value as an adjunct to standard treatment in congestive heart failure patients.

Keywords: congestive heart failure; lacidipine; peak oxygen consumption; neurohormones.

Chronic heart failure is a major public health problem. Despite angiotensin converting enzyme inhibitors, digoxin, and diuretics, both mortality and morbidity remain high. There is a compelling need for therapeutic alternatives or additives. The direct arterial vasodilator effect of the dihydropyridine calcium channel blockers results in a reduction of systemic vascular resistance. This may be beneficial as an adjunct to the indirect vasodilating angiotensin converting enzyme inhibitors. However, vasodilatation-induced neurohumoral activation and negative inotropic effects of the first generation of these dihydropyridines resulted in a disappointing outcome in heart failure studies. In recent years more selective dihydropyridine calcium antagonists have been developed, typified by a slow onset of action, a long plasma half life, and a narrow trough to peak ratio. This may result in less neurohormonal activation, while high vascular selectivity may lead to less negative inotropic effects. Lacidipine is one such new dihydropyridine derived vascular selective calcium antagonist with a slow onset and longer duration of action, which has been proven effective as an antihypertensive agent. This study, which is the first using lacidipine in heart failure patients, was designed to explore the efficacy and safety of lacidipine when given in conjunction with angiotensin converting enzyme inhibitors, digoxin, and diuretics.

Methods

STUDY DESIGN

The study was a prospective, double blind, randomised, placebo controlled, parallel group comparison (fig 1), performed in one centre (Ignatius Hospital, Breda). During a single blind, placebo run in period of 7–14 days clinical stability was confirmed and patient characteristics were obtained. Clinical stability was defined as unchanged New York Heart
Association classification, unchanged drug treatment, and reproducibility of the cardiopulmonary exercise tests. If a patient fulfilled all entry criteria at the end of this period he was eligible for the double blind treatment period with lacidipine 4 mg once daily or placebo. At baseline, echocardiography, plasma neurohormones, and invasive haemodynamic indices were obtained. During the study, patients were seen every two weeks in the outpatient department where a complete cardiovascular examination was performed and New York Heart Association class and adverse effects were evaluated. Adherence to study medication was checked by pill count. After eight weeks the clinical and haemodynamic evaluations were repeated, and a subjective assessment of general improvement or deterioration was made both by investigator and patient. The protocol was approved by the ethics committee of the Ignatius Hospital and was conducted in accordance with the revised Declaration of Helsinki. Before the study, all patients gave informed, written consent.

PATIENTS

Patients were included in this study if they fulfilled the following entry criteria: (A) age > 18 years; (B) stable heart failure (New York Heart Association class II–III), while on fixed medication (for at least six weeks) of angiotensin converting enzyme inhibitors (enalapril > 10 mg or captopril > 75 mg daily), digoxin and diuretics; (C) left ventricular ejection fraction < 0.40 as assessed by radionuclide ventriculography; (D) cardiothoracic ratio > 0.52 on chest x-ray or left ventricular end diastolic diameter > 5.5 cm by echocardiography; (E) reproducible and valid cardiopulmonary exercise test, which was limited by dyspnoea or fatigue, with a peak oxygen consumption > 10 and < 20 ml/kg/min.

Exclusion criteria included active myocarditis, obstructive cardiomyopathy, aortic stenosis or insufficiency, hypotension (systolic blood pressure < 105 mm Hg), myocardial infarction, coronary angioplasty or cardiac surgery (all within two months), ventricular demand pacemaker, symptomatic arrhythmia, atrial fibrillation or flutter with a ventricular response > 100 beats/min, supraventricular tachycardia > 120 beats/min, severe obstructive pulmonary disease, relevant hepatic, haematological or renal disease, phaeochromocytoma, psychiatric illness, and known intolerance of the study drug.

CARDIOPULMONARY EXERCISE TEST

Exercise testing with respiratory gas exchange was performed 1–3 h after intake of study medication, while patients exercised on an electronically braked bicycle ergometer (Erich Jaeger). The exercise protocol started at a workload of 20 W, with increments every 2 min by 20 W up to appearance of limiting dyspnoea or fatigue. Patients breathed through a mask into a mixing bag. Oxygen consumption, carbon dioxide production, and respiratory exchange ratios were measured continuously using an automated gas exchange measuring system (EOS sprint version 4.01, Erich Jaeger). All patients were familiar with the cardiopulmonary exercise test. Values were recorded at 30 s intervals. Heart rate and blood pressure, measured with a mercury sphygmomanometer, were recorded before, after every other minute during, at peak, and at 2 and 5 min after exercise. The electrocardiogram was monitored (Siemens Mingograf 410) using a bipolar lead system. Reasons for discontinuation of the exercise test during the double blind period were: symptom limited dyspnoea, fatigue or chest discomfort, severe or sustained (supra)ventricular arrhythmias, fall of > 20 mm Hg in systolic blood pressure during exercise, and increase in systolic blood pressure of > 250 mm Hg. Maximum achieved workload was defined as the maximum workload maintained for at least 30 s. Highest comparable submaximal workload, with 10 ml of cold isobutane 5% and in-line sensing of the injectate temperature. The average value of seven successive measurements was accepted if they varied by < 10%. Arterial and mixed venous (pulmonary) blood samples were drawn and analysed for O2 saturation (Instrumentation Laboratories 282). The following haemodynamic variables were recorded: heart rate, systemic and pulmonary arterial and venous pressures, arterial and mixed venous oxygen saturation, right atrial pressure, pulmonary capillary wedge pressure, cardiac output, and right ventricular ejection fraction. Cardiac index, systemic vascular resistance, stroke volume, and arteriovenous oxygen content difference.
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure

ence were calculated. The assessments were made two to three hours after the intake of the study medication.

**ASSESSMENT OF LEFT VENTRICULAR FUNCTION AT REST**

Left ventricular ejection fraction was obtained from the radionuclide ventriculography (multiple gated equilibrium technique). From the echocardiogram left ventricular end diastolic and end systolic diameters were obtained to calculate shortening fraction.

**PLASMA NEUROHUMORAL INDICES**

Blood for neurohumoral determinations was drawn after 30 min of supine rest, immediately centrifuged, and the plasma was frozen at −20°C. Analysis of plasma noradrenaline and aldosterone was done using a sensitive high performance liquid chromatography assay with electrochemical detection. Plasma renin activity was measured by radioimmunoassay (Dupont, Ria NEN kit No NEA-022, 026).

**STATISTICAL METHODS**

Indices of primary efficacy were the results of cardiopulmonary exercise tests: oxygen consumption, exercise time, and rate-pressure product (= systolic blood pressure × heart rate) at maximum achieved workload and at highest comparable submaximal workload. Secondary efficacy indices were the results from haemodynamic investigations and effects on plasma neurohormones. Safety indices consisted of effects on echocardiography variables, electrocardiogram, blood tests, and clinical events.

Comparisons were made with Student’s t test for normal distribution or with Wilcoxon two sample rank-sum test in case of abnormal distribution or ordinal response data. Mean differences between the treatments, with their standard deviations, are given unless indicated otherwise. All P values reported are for two tailed tests, and a P value < 0.05 was considered statistically significant.

**Results**

**PATIENTS**

Twenty five patients entered the study. Baseline characteristics are presented in table 1. There were no significant differences between the groups at baseline. Before unblinding of the trial code three patients were excluded from the efficacy analysis as they had not all had their final assessments performed according to the protocol; one patient (placebo) had a cerebrovascular accident caused by a cerebral tumour; one lacidipine patient had a lung metastasis of a Grawitz tumour (unknown at the time of inclusion); one patient (lacidipine) experienced worsening heart failure necessitating hospital admission. The remaining 22 patients form the study population for the efficacy indices: 12 were randomised to placebo and 10 to lacidipine. For peak oxygen consumption two additional analyses were performed with inclusion of the lacidipine patient who had been admitted to hospital with worsening heart failure. In the first analysis for peak oxygen consumption at the final visit this patient’s baseline peak oxygen value was used (that is, no change); in the second analysis the worst recorded value for peak oxygen consumption was taken.

<table>
<thead>
<tr>
<th>Table 1 Baseline demographic, clinical, neurohumoral, and haemodynamic characteristics. Values given are number of patients, and mean (SD).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medication</strong></td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Sex (male/female)</td>
</tr>
<tr>
<td>Height (cm)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Aetiology of heart failure (n)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Invasive haemodynamic variables</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Neurohormones</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**CARDIOPULMONARY EXERCISE TEST**

Peak oxygen consumption increased by 1-3 ml/min/kg to 16-1 (SD 3-4) with lacidipine and decreased by 6 ml/min/kg to 13-6 (2-2) with placebo (P<0-02 between treatments, fig 2). The two additional analyses revealed similar results with P values of 0-02 and 0-06 respectively. Exercise duration increased by 28 s to 538 (215) s with lacidipine, and decreased by 4 s to 486 (145) s with placebo (P = NS). At rest, submaximal and peak exercise, heart rate, and blood pressure remained unchanged (table 2).

**Figure 2** Individual and mean (bars = SD) peak oxygen consumption at baseline and after eight weeks of placebo treatment (left) and lacidipine treatment (right).
Table 2  Changes in bicycle cardiopulmonary exercise test indices compared with baseline. Values are means with the 95% confidence intervals given in parentheses

<table>
<thead>
<tr>
<th></th>
<th>Rest</th>
<th>Submaximal level</th>
<th>Peak exercise</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lacidipine</td>
<td>Placebo</td>
<td>Lacidipine</td>
</tr>
<tr>
<td>Rate-pressure product (mm Hg x beats/min)</td>
<td>-2 (-7.3)</td>
<td>-7 (-15.1)</td>
<td>-1367 (-3407,673)</td>
</tr>
<tr>
<td>Mean arterial blood pressure (mm Hg)</td>
<td>-7 (-14.0)</td>
<td>-5 (-12.1)</td>
<td>-1 (-7.5)</td>
</tr>
<tr>
<td>Oxygen consumption (ml O₂/min/kg)</td>
<td>-0.2 (-0.5;0.3)</td>
<td>0.1 (-0.5;0.4)</td>
<td>0.2 (-1;1.1)</td>
</tr>
<tr>
<td>Respiratory quotient</td>
<td>0.01 (-0.03;0.04)</td>
<td>0.02 (-0.03;0.04)</td>
<td>-0.03 (-0.10;0.04)</td>
</tr>
<tr>
<td>Exercise time (s)</td>
<td>0.01 (-0.02;0.04)</td>
<td>0.02 (-0.03;0.04)</td>
<td>-0.03 (-0.10;0.04)</td>
</tr>
</tbody>
</table>

*P < 0.02 lacidipine v placebo.

NEUROHUMORAL DATA
The individual values of neurohormones are shown in fig 3. Analysis revealed no statistically significant differences, but standard deviation was large.

HAEMODYNAMICS
Baseline haemodynamic data were comparable between both groups. After eight weeks of treatment, lacidipine, compared to placebo treatment and own baseline values, significantly reduced systemic vascular resistance by 302 dyn·sec·cm⁻⁵ to 1368 (412), pulmonary vascular resistance by 18 dyn·sec·cm⁻⁵ to 143 (113), and arteriovenous oxygen content difference by 0.85 ml O₂/100 ml to 4.65 (1.26). Lacidipine significantly increased cardiac index by 0.6 l/min·m⁻² to 3.5 (1.1) (fig 4). No significant changes between treatments were seen for arterial pressures, heart rate, pulmonary artery pressures, pulmonary capillary wedge pressure, right atrial pressure, right ventricular ejection fraction, or pulmonary vascular resistance. Placebo treatment did not change any of the haemodynamic variables.

RADIONUCLEIDE VENTRICULOGRAPHY AND ECHOCARDIOGRAPHY
Left ventricular ejection fraction, left ventricular end diastolic diameter, end systolic diameters, and shortening fraction did not change after treatment.

SIGNS AND SYMPTOMS OF HEART FAILURE
On lacidipine four patients improved clinically by one New York Heart Association class, six noted no change, and one experienced deterioration by one class. In the placebo group two patients improved and 10 experienced no change (NS). During the study one lacidipine patient was given additional glyceryl trinitrate and one patient was admitted to hospital. No other interventions or changes in medication were needed.

SAFETY ANALYSIS
Of the 25 patients studied, adverse events were reported by seven (60%) on lacidipine and four (31%) on placebo (NS). Neither treatment affected sitting to standing blood pressures. Serious adverse events were reported in three patients: one on placebo (cerebrovascular accident) and two on lacidipine (lung tumour and worsening of heart failure). There were no deaths during the study. Adherence to study medication was > 95% in all patients, as estimated by pill count. Results

![Figure 3](https://example.com/figure3.png)

Figure 3  Individual and mean (bars = SEM) neurohumoral variables at baseline and after eight weeks of placebo treatment (left) and lacidipine treatment (right). No statistical changes are observed within or between groups.
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure

Discussion

This exploratory study, the first using the new dihydropyridine calcium channel blocker lacidipine in patients with heart failure, shows that eight weeks of treatment with 4 mg lacidipine, given in conjunction with angiotensin converting enzyme inhibitors, digoxin, and diuretics, increases peak oxygen consumption during exercise and cardiac index at rest. These changes were accompanied by a decrease in systemic vascular resistance without change in arterial blood pressure in these normotensive heart failure patients. The observed changes in neurohumoral indices showed a wide variation but were not statistically different from placebo. Lacidipine did not induce orthostatic hypotension and was well tolerated overall although one lacidipine patient was admitted to hospital for worsening heart failure.

The baseline peak oxygen uptake of 14.4 ml/min/kg indicated impaired aerobic capacity.11 The small increase in peak oxygen consumption after eight weeks of treatment with lacidipine, together with an increase in cardiac index and decrease in arteriovenous oxygen content difference without changes in arterial oxygen content, suggests that the observed increase in flow is not shunted to different vascular beds but directed to oxygen consuming body areas in need of increased flow, such as skeletal muscles.

Other studies12–14 with second generation dihydropyridines (felodipine, amldipine, nisodipine) in heart failure patients have shown conflicting results. Kassis and Amtorp17 found an improvement in haemodynamic variables and neurohormones after felodipine. Amldipine18 decreased neurohormonal activation and prolonged exercise duration. Nisoldipine improved clinical status and did not influence neurohormones; however, the initial effects on haemodynamic variables disappeared after three months.14 Dunselman et al15 found an improvement in haemodynamics and in exercise duration after eight weeks of treatment with felodipine. Tan et al16 reported an improvement in haemodynamic variables with felodipine, but no improvement in clinical condition or exercise capacity after three weeks. Nicardipine resulted in worsening of heart failure and neurohumoral activation after four months of treatment.15 Apart from lack of uniformity in design and methodology of these studies, it is important to realise that no two dihydropyridines are the same, and that the differences in vasoselectivity, plasma half life, and peak to trough plasma level ratio may partly explain the observed differences in study results.

A cautious approach to our results with lacidipine on neurohumoral activation is justified as this was a small study. However, there are several possible explanations for the lack of overt neurohumoral activation despite pronounced arterial vasodilatation observed in our study and others. First, it may be caused by the increase in cardiac output which may be sufficient to compensate for the decrease in blood pressure, thereby abolishing the need for a heightened compensatory neurohumoral mechanism. If this explanation is true one should have expected the same results with other vasodilators like hydralazine which also result in a significant increase in cardiac output, though associated with neurohumoral activation. Second, the confounding effects of comedication have to be considered as a possible source of the observed beneficial effects of lacidipine in our study. Effects of both angiotensin converting enzyme inhibitors and digoxin in heart failure patients may be partly related to their effect on neurohumoral mechanisms, decreasing the activation of the sympathetic nervous system and the renin-angiotensin axis,19,20 thereby neutralising or obscuring a possible neurohumoral activation of dihydropyridines. Third, resetting of baroreceptor sensitivity by dihydropyridines, resulting in less sympathetic activation, may play a role.17 Finally, the pharmacokinetic profile of this new dihydropyridine, typified by a slow onset of action, longer duration of action, and narrow trough to peak variability, may attribute to this effect.

Although haemodynamic and exercise vari-
ables improved significantly, no changes in left ventricular systolic function at rest were found. Ejection fraction is a strong prognostic marker in heart failure patients21 but our findings may underestimate the fact that for evaluation of drug induced haemodynamic changes in a small patient group, this non-invasive assessment lacks sensitivity.22 However, the lack of change in left and right ejection fractions and shortening fraction suggests that lacidipine treatment did not result in a deterioration of systolic function, as described with the first generation of dihydropyridines.24 25

STUDY LIMITATIONS
The number of patients studied was small and therefore the data must be interpreted with caution. An imbalance in sex over the two treatment groups existed (albeit non-significant) which may have influenced the outcome. We cannot rule out the possibility that a neurohumoral counterregulation could go undetected owing to the small number of patients in our study and the large variation in neurohumoral plasma levels.

CLINICAL IMPLICATIONS
The aetiology of heart failure is coronary artery disease or hypertension in 60–70% of cases,26 27 and these patients may benefit from the use of additional calcium channel blockers since they lead to both peripheral and coronary vasodilatation.28 Both the prevention and the treatment trial of the studies of left ventricular dysfunction (SOLVD) showed that more than 30% of patients fulfilling the entry criteria were using a calcium channel blocker,29 indicating that physicians keep patients on these drugs prescribed for hypertension or coronary artery disease even when symptomatic systolic dysfunction develops. This study in patients with heart failure showed that lacidipine, in conjunction with angiotensin converting enzyme inhibitors, digoxin, and diuretics, improves aerobic capacity, maintains vasodilatation, does not have a major influence on neurohumoral activity, and is generally well tolerated. When a physician considers prescribing a calcium channel blocker to a patient with heart failure—because of hypertension or angina pectoris—second generation calcium antagonists like lacidipine may be preferred to the first generation calcium antagonists. However, with respect to the long-term efficacy and safety of second generation dihydropyridines in heart failure, the results of the V-Heft III [evaluating felodipine compared to placebo in addition to diuretics, angiotensin converting enzyme inhibitors, and digoxin], and the Praise Study [amlodipine versus placebo in addition to angiotensin converting enzyme inhibitors]11 must be awaited.

We express our gratitude to our research nurse Jacqueline Koning for her assistance in the care of the patients and to Dr G Ziegler (BUCAM, Clinical Research Organisation, Basel, Switzerland) and Dr W Sauermann (DATAMAP, Statistical Analysis, Freiburg, Germany) for data handling and analysis. This study was supported by a grant from Glaxo Verona, Italy.


Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure.


*Heart* 1996 75: 159-164
doi: 10.1136/hrt.75.2.159

Updated information and services can be found at:
http://heart.bmj.com/content/75/2/159

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/